Tango Therapeutics
Tango Therapeutics' revenue rose 48.3% to $62 million in fiscal 2025. Its operating margin was −178.4%, up from −346.1% a year earlier. Free cash flow was −$140 million. The diluted share count rose 6.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Tango Therapeutics does
Tango Therapeutics is a drug developer focused on cancer. It looks for medicines that work against cancer cells with specific genetic changes while sparing normal cells. It has no products approved for sale and has not earned revenue from product sales.
Its work is centered on two experimental drugs that block a protein called PRMT5 in cancers that lack a gene called MTAP. Vopimetostat (TNG462) is aimed at cancers outside the brain and spinal cord, both alone and combined with drugs that block RAS, a common cancer-driving protein. TNG456 is designed to reach the brain and is aimed at brain cancers, including glioblastoma. In October 2025 the company reported data from an ongoing Phase 1/2 trial of vopimetostat, and it plans to start a pivotal trial in second-line pancreatic cancer in 2026.
Tango pays for its research by raising money from investors and through partnerships, not by selling medicines. It runs combination trials with drugs from Revolution Medicines, and in March 2026 it agreed to test vopimetostat alongside a drug from Erasca. It also has a discovery program that looks for new targets. At the end of 2025 it had 137 full-time employees, most of them in research and development.
Its biggest risks, as it describes them
- It has no approved products, has never earned product revenue, and may never become profitable.
- It has lost money since it began and will need to raise a lot more funding, which could dilute shareholders.
- Its drugs may fail in clinical trials, show safety problems, or be delayed or not approved.
- Early results may not hold up in later trials, and trial data it announces can change.
- Competitors may develop rival cancer treatments first, and its approach is new and unproven.
Income statement
Tango Therapeutics lost money in fiscal 2025: a net loss of $102 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 485 | 366 | 337 | 258 | 343 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 12.1x | 6.8x | 7.5x | 7.0x | 16.3x |
| Quick ratio | 12.1x | 6.8x | 7.5x | 7.0x | 16.3x |
Cash flow
Projections
Project Tango Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Tango Therapeutics shares on the open market, and 4 insiders sold $7.2 million, $6.4 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | Adam CrystalPresident, R&D | Sold plan | 5,000 | $25.00 | $125,000 | Form 4 |
| Sep 22, 2026 | Jessica NewcombPrincipal Accounting Officer | Sold plan | 8,200 | $24.22 | $198,615 | Form 4 |
| Sep 1, 2026 | Adam CrystalPresident, R&D | Sold plan | 27,000 | $22.37 | $603,990 | Form 4 |
| Aug 3, 2026 | Adam CrystalPresident, R&D | Sold plan | 27,000 | $27.24 | $735,500 | Form 4 |
| Jul 1, 2026 | Adam CrystalPresident, R&D | Sold plan | 27,000 | $29.59 | $798,888 | Form 4 |
| Jun 1, 2026 | Adam CrystalPresident, R&D | Sold plan | 27,000 | $22.88 | $617,647 | Form 4 |
| May 1, 2026 | Adam CrystalPresident, R&D | Sold plan | 27,000 | $21.22 | $573,021 | Form 4 |
| Apr 15, 2026 | Adam CrystalPresident, R&D | Sold plan | 38,460 | $25.00 | $961,500 | Form 4 |
| Apr 1, 2026 | Adam CrystalPresident, R&D | Sold plan | 27,000 | $21.20 | $572,400 | Form 4 |
| Mar 25, 2026 | Adam CrystalPresident, R&D | Sold plan | 12,000 | $20.11 | $241,320 | Form 4 |
| Mar 5, 2026 | Adam CrystalPresident, R&D | Sold plan | 20,251 | $15.00 | $303,765 | Form 4 |
| Feb 25, 2026 | Adam CrystalPresident, R&D | Sold plan | 54,345 | $12.77 | $693,986 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −280.2% | −299.2% | −176.0% |
| Altman Z'' | 1.76 | −1.74 | 5.58 |
| Accruals ratio | 3.9% | 0.3% | 10.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Fail | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Tango Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Tango Therapeutics | FY25 | 48.3% | −178.4% | −224.3% | — | — | — | |
| Nuvation Bio | FY25 | 699.0% | −338.7% | −288.4% | — | — | — | Compare |
| Kura Oncology | FY25 | 25.2% | −449.9% | −104.8% | — | — | 3 | Compare |
| Nektar Therapeutics | FY25 | −43.9% | −253.7% | −377.8% | — | — | 2 | Compare |
| Viridian Therapeutics | FY25 | 23,359.9% | −512.9% | −390.8% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 8 | 37 | 25 | 36 | 42 | 62 |
| Revenue growth | — | 383.8% | −32.9% | 46.9% | 15.2% | 48.3% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 50 | 78 | 106 | 115 | 144 | 132 |
| Operating income | −52 | −58 | −111 | −114 | −146 | −111 |
| Net income | −52 | −58 | −108 | −102 | −130 | −102 |
| Diluted EPS (US$) | −1.63 | −0.94 | −1.23 | −1.08 | −1.19 | −0.87 |
| Diluted shares (millions) | 32 | 62 | 88 | 95 | 109 | 116 |
| Cash flow | ||||||
| Cash from operations | 70 | −60 | −109 | −118 | −132 | −139 |
| Capital expenditure | 1 | 2 | 8 | 2 | 1 | 1 |
| Free cash flow | 69 | −61 | −117 | −120 | −132 | −140 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 8 | 14 | 19 | 29 | 26 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 190 | 485 | 366 | 337 | 258 | 343 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | 207 | 500 | 436 | 403 | 316 | 399 |
| Total liabilities | 169 | 155 | 187 | 150 | 117 | 52 |
| Shareholders' equity | 39 | 345 | 250 | 253 | 200 | 346 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | −681.8% | −157.1% | −446.8% | −312.6% | −346.1% | −178.4% |
| Net margin | −678.8% | −157.2% | −435.1% | −278.5% | −309.7% | −162.8% |
| Free cash flow margin | 900.8% | −165.7% | −469.7% | −327.2% | −314.4% | −224.3% |
| Rule of 40 (growth + FCF margin) | — | 218.2% | −502.6% | −280.2% | −299.2% | −176.0% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −30.4% | −36.4% | −40.5% | −57.6% | −37.2% |
| Return on assets | — | −16.5% | −23.1% | −24.2% | −36.2% | −28.4% |
| Net debt to EBITDA | — | — | — | — | — | — |